SUPERNUS PHARMACEUTICALS, INC. — Form 10-Q
Filed October 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Jack A. Khattar (President/CEO) and Timothy C. Dec (SVP/CFO) certified Supernus Pharmaceuticals' Form 10-Q for the quarter ended September 30, 2026, filed October 29, 2026. Both officers certified under SOX 302 and 906 that the report contains no untrue material statements, that financial statements fairly present the company's condition, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud were disclosed.
Why this rating
Standard quarterly certification with no disclosed control deficiencies or material issues. Routine compliance filing; absence of red flags is baseline expectation.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.